Phone: 959-333-0983
Phone: 959-333-0983
Original price was: $236.96.$179.99Current price is: $179.99.
This item has been third-party tested by accredited U.S. laboratories and confirmed to meet a minimum purity of 98% through rigorous verification standards.
Original price was: $236.96.$179.99Current price is: $179.99.
Lyophilized powders in sterile glass vials.
Independently analyzed by an accredited third-party lab.
KLOW Peptides confirmed by mass spectrometry.
Supplied exclusively for laboratory investigation.
| Compound Class | Synthetic Pentadecapeptide (Gastric Protective Protein Fragment) |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| CAS Number | 137525-51-0 |
| Chemical Formula | C62H98N16O22 |
| Molar Mass | 1419.53 g/mol |
| Synonyms | BPC-157, Body Protection Compound-157, Bepecin, PL 14736 |
| Verified Purity | Batch-tested to 98% (HPLC) |
| Compound Class | Synthetic Actin-Binding Regulatory Protein |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| CAS Number | 77591-33-4 |
| Chemical Formula | C212H350N56O78S |
| Molar Mass | ~4963 g/mol |
| Synonyms | TB-500, Thymosin Beta-4, Tβ4 |
| Verified Purity | Batch-tested to 98% (HPLC) |
| Compound Class | Synthetic Tripeptide (α-MSH C-terminal Fragment) |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 5 mg |
| Sequence | Lys-Pro-Val |
| CAS Number | 67727-97-3 |
| Chemical Formula | C16H30N404 |
| Molar Mass | 342.43 g/mol |
| Synonyms | KPV, Lysine-Proline-Valine, α-MSH (11-13) |
| Verified Purity | Batch-tested to 98% (HPLC) |
| Compound Class | Copper-Binding Tripeptide Complex |
|---|---|
| Form | Lyophilized powder, sterile glass vial |
| Amount per Vial | 50 mg |
| Sequence | Gly-His-Lys, complexed with Cu2+ |
| CAS Number | 49557-75-7 |
| Chemical Formula | C14H24CuN6O4 |
| Molar Mass | 403.9 g/mol |
| Synonyms | GHK-Cu, Copper Peptide, Copper Tripeptide-1 |
| Verified Purity | Batch-tested to 98% (HPLC) |
Each peptide batch is analyzed by an accredited third-party laboratory before it ships.
Every batch sold by Research Chemical is independently analyzed before it ships.
This product is an investigational compound and is not a drug, food, dietary supplement, or cosmetic. It is not approved for human or animal use, and it is unlawful to market it for that purpose.
The KLOW Stack is prohibited by the World Anti-Doping Agency (WADA) at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
Research Chemical makes no representations regarding the safety or effects of this compound in humans or animals.
Research Chemical is a chemical supplier, not a medical provider. We do not condone or encourage consumer use of research compounds.
Research use only. All products sold by Research Chemical are intended exclusively for laboratory research and development. They are not for human or animal consumption. These statements have not been evaluated by the U.S. Food and Drug Administration, and these products are not intended to diagnose, treat, cure, or prevent any disease.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
1. Sikiric P, Seiwerth S, Grabarevic Z, et al. BPC 157’s effect on healing. Journal of Physiology and Pharmacology. 2009 Dec;60(Suppl 7): Suppl 2: 191-6. PMID: 20572349.
2. Chang CH, Tsai WC, Lin MS, et al. Effects of pentadecapeptide BPC 157 on tendon healing in a rat model. Journal of Orthopaedic Research. 2011 Aug;29(8): 1174-80. Doi: 10.1002/jor.21367.
3. Klicek R, Sever M, Radic B, et al. Gastric pentadecapeptide BPC-157 accelerates the healing of transected rat Achilles tendons and in vitro stimulates tendocyte growth. Journal of Orthopaedic Research. 2003;21(6):976-83. Doi: 10.1016/S0736-0266(03)00081-1.
4. Mogoşanu, G. D., & Grumezescu, A. M. (2014). Natural and synthetic polymers for wound and burn dressing. International journal of pharmaceutics, 463(2), 127-136.
5. Krivic A, Anic T, Seiwerth S, et al. Achilles Detachment in Rat and Stable Gastric Pentadecapeptide BPC-157: Promoted Tendon-to-Bone Healing and Opposed Corticosteroid Adverse Effects. Journal of Orthopaedic Research. 2006 Jun;24(6):982-93. Doi: 10.1002/jor.20096.
6. Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. S. (2011). The promoting effect of pentadecapeptide BPC-157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3), 774-780.
7. Duzel, A., Vlainic, J., Antunovic, M., Malekinusic, D., Vrdoljak, B., Samara, M., … & Sikiric, P. (2017). Stable gastric pentadecapeptide BPC-157 in the treatment of colitis and ischemia and reperfusion in rats: New insights. World Journal of Gastroenterology, 23(48), 8465.
8. Sikiric P, et al. Stable gastric pentadecapeptide BPC-157 in the treatment of colitis and ischemia and reperfusion in rats: new insights. World Journal of Gastroenterology. 2017;23(48): 8465-8488. doi: 10.3748/wjg.v23.i48.8465.
9. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL14736) (gep-bpc-157). Current Pharmaceutical Design. 2018;24(2): 190-195. Doi: 10.2174/1381612823666170829095955.
10. Stupnisek M, et al. Pentadecapeptide BPC-157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colo-rectal fistulas in rats: role of the nitric oxide system. Journal of Pharmacological Sciences. 2017;133(4): 201-208. doi: 10.1016/j.jphs.2017.07.009.
11. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005 Aug;11(8): 354-61.
12. Post A, Al-Rawi M, Sumitran-Holgersson S. In vivo tissue repair activity of thymosin beta-4 in wound healing. Annals of the New York Academy of Sciences. 2007 Sep;1112: 177-81. doi: 10.1196/annals. 1415.019.
13. Hinkel, R., El-Aouni, C., Olson, T., Horstkotte, J., Mayer, S., Müller, S., … & Kupatt, C. (2008). Thymosin β4 is an essential paracrine factor of embryonic endothelial progenitor cell–mediated cardioprotection. Circulation, 117(17), 2232-2240.
14. Belsky, J. B., Rivers, E. P., Filbin, M. R., Lee, P. J., & Morris, D. C. (2018). Thymosin beta 4 regulation of actin in sepsis. Expert opinion on biological therapy, 18(sup1), 193-197.
15. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004 Apr;432(7016): 466-72. doi: 10.1038/nature03000.
16. Goldstein, A. L., Hannappel, E., Sosne, G., & Kleinman, H. K. (2012). Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert opinion on biological therapy, 12(1), 37-51.
17. Sosne, G., Rimmer, D., Kleinman, H. K., & Ousler, G. (2016). Thymosin beta 4: a potential novel therapy for neurotrophic keratopathy, dry eye, and ocular surface diseases. Vitamins and hormones, 102, 277-306.
18. Smart, N., Risebro, C. A., Melville, A. A., Moses, K., Schwartz, R. J., Chien, K. R., & Riley, P. R. (2007). Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature, 445(7124), 177-182.
Please note that the above references provide evidence for the potential benefits of BPC-157 Peptide and Ipamorelin Peptide as stated in the product description. For more in-depth information, refer to these scholarly works.
Join our insider list for the latest research insights and sales